Compare ADMA Biologics Inc (ADMA) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $59.58 (market cap $77.30B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 36.3× ADMA Biologics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.32% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MDLZ | |
|---|---|---|
Market Cap | $2.13B | $77.30B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $70.75 |
52-Week Low | $7.60 | $51.51 |
Enterprise Value | $2.20B | $97.40B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
MDLZ trades at $60.22, down 1.13% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 75.6% analyst buy rating. Revenue grew to $38.54B in 2025, though net margin compressed to 6.36%. Recent news highlights innovation in brands like Toblerone and Sour Patch Kids, alongside a new CFO appointment and a $0.50 dividend declaration.
Outlook: Wall Street consensus target of $67.86 suggests 12.7% upside, supported by resilient snacking demand and cost management. Risks include cocoa price volatility and competitive pressures, but the stock offers value with a P/E of 29.3 and stable cash flows, positioning it for recovery if technical resistance at $61 is breached.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
